Incannex Healthcare Inc. (IXHL)

Incannex Healthcare’s lead IHL-42X program has advanced into active Phase 2 clinical execution for obstructive sleep apnea, with dosing underway across about 120 patientsat 14 U.S. sites. The company reported roughly $68.4 million in unrestricted cashas of September 24, while Stonegate expects additional funding will be needed after the current operating runway. IXHL is up 5.67% today on a full-day basis, with recent coverage centered on clinical execution, funding, and pipeline prioritization.